A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2017
At a glance
- Drugs AUT 00206 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; First in man
- Sponsors Autifony Therapeutics
- 10 Jan 2017 Results assessing Mismatch Negativity (MMN) latency published in an Autifony Therapeutics Media Release
- 01 Aug 2016 Status changed from recruiting to completed, as reported in an Autifony Therapeutics media release.
- 27 Oct 2015 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.